NeuroStim TMS has introduced One-Day TMS™, a novel accelerated form of Transcranial Magnetic Stimulation (TMS) delivering a complete therapeutic course in one day, compared to the typical 30–36 sessions over several weeks, the company said that it offers faster access to treatment.
The ONE-D Protocol (Optimized, Neuroplasticity-Enhanced Depression Treatment), co-invented by Jonathan Downar, MD, PhD, delivers 20 TMS sessions in a single visit. According to the company, the ONE-D clinical study showed over 90% of participants achieved significant improvement and more than 75% achieved full remission. All 32 patients completed treatment without any major side effects.
Unlike other accelerated protocols like Stanford’s SAINT—which involves more sessions across multiple days, higher pulse counts, and functional MRI for targeting—ONE-D uses heuristic targeting, fewer pulses (12,000 vs. SAINT’s 90,000), and does not require imaging. The company claims this enhances convenience and accessibility.
The new protocol also incorporates two one-time, low-dose supportive medications—D-cycloserine and lisdexamfetamine—administered at the start of treatment to promote neuroplasticity, the company said that this is key to making the single-day format possible.
NeuroStim TMS added that more than 150 patients have since received the single-day protocol, with outcomes that meet or often exceed standard TMS remission results and without major side effects. Follow-up with over 100 patients indicated that most remained in remission six months later.
Currently, One-Day TMS™ is not yet covered by insurance, though standard TMS is covered by most major insurers. NeuroStim is a national TMS provider and research center, having delivered over 250,000 treatments across sixteen locations in Washington, Arizona, and Minnesota.
